Program
VIS-101
A development code. Also written as “ASKG712”, “VIS-101 6.0mg Low concentration” and “VIS-101 6.0mg High concentration”.
Its studies are mostly in Macular Degeneration · Macular Edema, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Visara | 20 open or running | phase 2since Jul 6, 2022 | Jul 6, 2022 | none ahead |
| AffaMed Therapeutics | 10 open or running | phase 1since Apr 12, 2022 | Apr 12, 2022 | none ahead |
| Everest Medicines (China) | 11 open or running | phase 2since Aug 27, 2026 | Aug 27, 2026 | Jul 2028phase 2 · NCT07798375 |
Also a collaborator on its studies: Beijing Aosaikang Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 12, 2022First study: phase 1 study in Neovascular Age-related Macular DegenerationNew to AffaMed TherapeuticsAffaMed Therapeutics · NCT05345769 · 21 enrolled · United States
- Jul 6, 2022Visara's first study: phase 2 study in Neovascular Age-related Macular DegenerationNew to VisaraVisara · NCT05456828 · 56 enrolled · China
- May 11, 2023Phase 1 study in Diabetic Macular EdemaVisara · NCT05940428 · 10 enrolled · China
- Aug 27, 2026Everest Medicines (China)'s first study: phase 2 study in Macular DegenerationNew to Everest Medicines (China)Everest Medicines (China) · NCT07798375 · 244 planned
Ahead
- Jul 2028Primary completion: phase 2 study in Macular DegenerationEverest Medicines (China) · NCT07798375
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07798375Macular Degeneration | 2 | Not yet recruiting | Everest Medicines (China) | Jul 2028 | 244 |
| NCT05940428Diabetic Macular Edema · China | 1 | Completed | Visara | Oct 21, 2024 | 10 |
| NCT05456828Neovascular Age-related Macular Degeneration · China | 2 | Completed | Visara | Nov 3, 2025 | 56 |
| NCT05345769Neovascular Age-related Macular Degeneration · United States | 1 | Completed | AffaMed Therapeutics | Nov 4, 2024 | 21 |
How it is read
Names in the registry
- “ASKG712”, 2 entries
- “VIS-101 6.0mg Low concentration”, 1 entry
- “VIS-101 6.0mg High concentration”, 1 entry
- “VIS-101 9.0mg High concentration”, 1 entry
- “AM712(ASKG712)”, 1 entry
Codes read as this program: VIS101, ASKG712, AM712.
Conditions, from the studies’ own filings
- Macular Degeneration, 3 studies
- Macular Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.